Journal of Bioequivalence & Bioavailability

Dylst P

Publications

• Research Article
  Policy Practices to Maximise Social Benefit from Biosimilars
  Author(s): Inotai A, Csanádi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P and Kaló Z Inotai A, Csanádi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P and Kaló Z
  
  Biosimilar medicines can generate savings to the society. However, if patient access to original biologic medicines is limited, the main benefit of biosimilar medicines is to treat more patients from the same health care budget and hence generate more health gain. The aim of this policy paper is to provide recommendations on how to maximise the value proposition of biosimilar medicines in lower income countries with more limited health care resources. From the clinical perspective, first line use of multi-source, off-patent biologics should be considered for all treatment naïve patients before prescribing any other patented biologic therapies without major added benefit. Systematic literature reviews indicate that significant and quantifiable economic benefits from switching patients on maintenance biologic to biosimilars should not be sacrificed for non-quant.. View More»
  DOI: 10.4172/jbb.1000346

  Abstract PDF